Intermune's Esbriet spells hope for Cell Therapeutics' Pixuvri in Germany
This article was originally published in Scrip
Executive Summary
Cell Therapeutics is not too worried that an initial negative assessment from a health technology appraisal institute will mean the end for its Pixuvri (pixantrone) in Germany. Drugs that have gone before it, including Intermune's Esbriet (pirfenidone), give the firm hope, said the company.